# US 2025/0325643 A1 · Binding agents capable of binding to cd27 in combination therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0325643 A1
- Document ID: US20250325643A1
- Status: Published application
- Kind: A1
- Application number: 18/861,928
- Filed: 2023-05-12
- Published: 2025-10-23
- Earliest claimed: 2022-05-12
- Assignees: Genmab A/S; BioNTech SE
- Applicants: Genmab A/S; Biontech SE
- Inventors: Esther C. W. BREIJ; Ugur SAHIN; Isil ALTINTAS; Andreea IOAN; Frank BEURSKENS; Rob N. DE JONG; Janine SCHUURMAN; Pauline Linda DE GOEJE; David SATIJN; Peter BOROSS; Andrea IMLE; Kristina NÜRMBERGER; Alexander MUIK; Friederike GIESEKE
- Web page: https://patentgrep.com/patent/US20250325643A1

## CPC

- A61K 39/001117: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30}
- A61P 35/00: Antineoplastic agents
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides combination therapy using a first binding agent comprising at least one binding region binding to CD27 in combination with a second binding agent comprising a first binding region binding to CD40 and a second binding region binding to CD137 to reduce progression or prevent progression of a tumor or treating cancer.

## Claims

### Claim 1

A method for reducing progression or preventing progression of a tumor or treating cancer in a subject, said method comprising administering to said subject
i) a first binding agent comprises at least one binding region binding to CD27; and
ii) a second binding agent comprises a first binding region binding to CD40 and a second binding region binding to CD137.

### Claim 2 (depends on 1)

The method of claim 1, wherein said first binding agent comprises a heavy chain variable (VH) region CDR1, CDR2, and CDR3 comprising the sequences as set forth in SEQ ID NOs: 5, 6, and 7, respectively, and a light chain variable (VL) region CDR1, CDR2, and CDR3 comprising the sequences as set forth in SEQ ID NO: 9, 10 and 11, respectively.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein said first binding agent comprises two binding regions capable of binding to human CD27 wherein said first binding agent comprises the heavy chain variable (VH) region CDR1, CDR2, and CDR3 comprising the sequences as set forth in SEQ ID NOs: 5, 6, and 7, respectively, and the light chain variable (VL) region CDR1, CDR2, and CDR3 comprising the sequences as set forth in SEQ ID NO: 9, 10, and 11, respectively.

### Claim 4

The method of any one of the preceding claims, wherein said first binding agent comprises a VH region comprising a sequence as set forth in SEQ ID NO: 4.

### Claim 5

The method of any one of the preceding claims, wherein said first binding agent comprises a VL region comprising a sequence as set forth in SEQ ID NO: 8.

### Claim 6

The method of any one of the preceding claims, wherein said first binding agent comprises the VH and VL regions comprising the sequences as set forth in SEQ ID NO: 4 and SEQ ID NO: 8, respectively.

### Claim 7

The method of any one of the preceding claims, wherein said first binding agent is an antibody, preferably a human or a humanized antibody.

### Claim 8

The method of any one of the preceding claims, wherein the antibody is a full-length antibody further comprising a light chain constant region (CL) and a heavy chain constant region (CH).

### Claim 9 (depends on 8)

The method of claim 8, wherein the light chain constant region is human kappa.

### Claim 10 (depends on 8)

The method of claim 8, wherein the light chain constant region is human lambda.

### Claim 11

The method of any one of the preceding claims, wherein said first binding agent further comprises a heavy chain constant region, which is of a human IgG isotype, optionally of a modified human IgG.

### Claim 12 (depends on 11)

The method of claim 11, wherein the human IgG or modified human IgG is selected from IgG1, IgG2, IgG3 or IgG4, such as human IgG1.

### Claim 13 (depends on 11, 12)

The method of claim 11 or 12, wherein the IgG is a modified human IgG comprising one or more amino acid substitutions.

### Claim 14 (depends on 11, 12, 13)

The method of any one of claims 11 to 13, wherein the modified human IgG is a modified human IgG1 comprising one or more amino acid substitutions, such as two or more amino acid substitutions.

### Claim 15 (depends on 11, 12, 13, 14)

The method of any one of claims 11 to 14, wherein the modified human IgG heavy chain constant region comprises at most 10 amino acid substitutions, such as at most 9, such as at most 8, such as at most 7, such as at most 6, such as at most 5, such as at most 4, such as at most 3, such as at most 2 amino acid substitutions.

### Claim 16 (depends on 11, 12, 13, 14, 15)

The method of any one of claims 11 to 15, wherein said substitution in the heavy chain constant region induces increased CD27 agonism compared to an identical antibody except for comprising a wild type IgG1 antibody heavy chain constant region.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

The method of any one of claims 11 to 16, wherein the amino acid residue at the position corresponding to position E345 or E430 in a human IgG1 heavy chain according to Eu numbering is selected from the group comprising: A, C, D, F, G, H, I, K, L, M, N, Q, R, S, T, V, W and Y.

### Claim 18 (depends on 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 11 to 17, wherein the amino acid residue at the position corresponding to position E345 in a human IgG1 heavy chain according to Eu numbering is R.

### Claim 19 (depends on 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 11 to 18, wherein the amino acid residue at the position corresponding to position E430 in a human IgG1 heavy chain according to Eu numbering is G.

### Claim 20 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 11 to 19, wherein the amino acid residue at the position corresponding to position P329 in a human IgG1 heavy chain according to Eu numbering is R.

### Claim 21 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 11 to 20, wherein the amino acid residue at the positions corresponding to position E345 and P329 in a human IgG1 heavy chain according to Eu numbering are both R.

### Claim 22 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 11 to 21, wherein the first binding agent has a pharmacokinetic profile as the parent antibody comprising a wild type IgG1 heavy chain constant region.

### Claim 23

The method of any one of the preceding claims, wherein the first binding agent comprises the heavy chain constant region comprising a sequence selected from the group comprising: SEQ ID No 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 27, 28, 29, 30, 31, 32, 33, 34 and 36.

### Claim 24

The method of any one of the preceding claims, wherein the first binding agent comprises the heavy chain constant region comprising the sequence as set forth in SEQ ID No 15.

### Claim 25

The method of any one of the preceding claims, wherein said first binding agent comprises a heavy chain constant region, which is modified so that the first binding agent induces one or more Fc-mediated effector functions to a lesser extent relative to a parent antibody.

### Claim 26 (depends on 25)

The method of claim 25, wherein the one or more Fc-mediated effector functions is decreased by at least 20%, such as by at least 30% or by at least 40%, or by at least 50% or by at least 60% or by at least 70%, or by at least 80% or by at least 90%.

### Claim 27 (depends on 25, 26)

The method of claim 25 or 26, wherein the first binding agent does not induce one or more Fc-mediated effector functions.

### Claim 28 (depends on 25, 26, 27)

The method of any one of claims 25 to 27, wherein the one or more Fc-mediated effector functions is selected from the following group: complement-dependent cytotoxicity (CDC), complement-dependent cell-mediated cytotoxicity (CDCC), complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), C1q binding and FcγR binding.

### Claim 29 (depends on 25, 26, 27, 28)

The method of any one of claims 25 to 28, wherein the first binding agent does not induce C1q binding when measured by the method of Example 8.

### Claim 30

The method of any one of the preceding claims, wherein the first binding agent is a monovalent antibody.

### Claim 31

The method of any one of the preceding claims, wherein the first binding agent is a bivalent antibody.

### Claim 32

The method of any one of the preceding claims, wherein the first binding agent is a monospecific antibody.

### Claim 33

The method of any one of the preceding claims, wherein the first binding agent is a bispecific antibody comprising a first antigen binding region capable of binding human CD27 according to any one of the preceding claims and comprising a second antigen binding region capable of binding to a different epitope on human CD27 or capable of binding a different target.

### Claim 34

The method of any one of the preceding claims, wherein CD27 is human CD27, in particular said human CD27 comprises the sequence as set forth in SEQ ID NO: 1 or the human CD27 variant as set forth in SEQ ID NO: 2.

### Claim 35

The method of any one of the preceding claims, wherein said first binding agent comprises:
e. The VH region comprising the amino acid sequence set forth in SEQ ID No: 4;
f. The VL region comprising the amino acid sequence set forth in SEQ ID No: 8;
g. The CH region comprising the amino acid sequence set forth in SEQ ID No: 15; and
h. The CL region comprising the amino acid sequence set forth in SEQ ID No: 17.

### Claim 36

The method of any one of the preceding claims, wherein said first binding agent comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 35 and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 25.

### Claim 37

The method of any one of the preceding claims, wherein the first binding agent is in a composition or formulation comprising acetate, sorbitol, polysorbate 80, and has a pH from 5 to 6, preferably 5.5.

### Claim 38

The method of any one of the preceding claims, wherein CD40 is human CD40, in particular human CD40 comprising the sequence set forth in SEQ ID NO: 62, and/or CD137 is human CD137, in particular human CD137 comprising the sequence set forth in SEQ ID NO: 63.

### Claim 39

The method of any one of the preceding claims, wherein a) the first binding region of the second binding agent comprises a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 44, 45, and 46, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 47, YTS, and SEQ ID NO: 48, respectively; and b) the second binding region of the second binding agent comprises a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 51, 52, and 53, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 54, GAS, and SEQ ID NO: 55, respectively.

### Claim 40

The method of any one of the preceding claims, wherein
a) the first binding region of the second binding agent comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 49 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 50; and
b) the second binding region of the second binding agent comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 56 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 57.

### Claim 41

The method of any one of the preceding claims, wherein the second binding agent is a multispecific antibody, such as a bispecific antibody.

### Claim 42

The method of any one of the preceding claims, wherein the second binding agent is in the format of a full-length antibody or an antibody fragment.

### Claim 43

The method of any one of the preceding claims, wherein the second binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises
i) a polypeptide comprising said first heavy chain variable region (VH) and a first heavy chain constant region (CH), and
ii) a polypeptide comprising said first light chain variable region (VL) and a first light chain constant region (CL);
and the second binding arm comprises iii) a polypeptide comprising said second heavy chain variable region (VH) and a second heavy chain constant region (CH), and
iv) a polypeptide comprising said second light chain variable region (VL) and a second light chain constant region (CL).

### Claim 44

The method of any one of the preceding claims, wherein said second binding agent comprises
i) a first heavy chain and light chain comprising said first binding region capable of binding to CD40, the first heavy chain comprising a first heavy chain constant region and the first light chain comprising a first light chain constant region; and
ii) a second heavy chain and light chain comprising said second binding region capable of binding CD137, the second heavy chain comprising a second heavy chain constant region and the second light chain comprising a second light chain constant region.

### Claim 45 (depends on 43, 44)

The method of claim 43 or 44, wherein (i) the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said first heavy chain constant region (CH), and the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said second heavy chain constant region (CH), or (ii) the amino acid in the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R in said first heavy chain, and the amino acid in the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L in said second heavy chain.

### Claim 46 (depends on 43, 44, 45)

The method of any one of claim 43-45, wherein the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain according to EU numbering are F and E, respectively, in said first and second heavy chains.

### Claim 47 (depends on 43, 44, 45, 46)

The method of any one of claim 43-46, wherein the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively, in said first and second heavy chain constant regions (HCs).

### Claim 48 (depends on 43, 44, 45, 46, 47)

The method of any one of claims 43-47, wherein the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain according to EU numbering of both the first and second heavy chain constant regions are F and E, respectively, and wherein (i) the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the first heavy chain constant region is L, and the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the second heavy chain is R, or (ii) the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the first heavy chain constant region is R, and the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the second heavy chain is L.

### Claim 49 (depends on 43, 44, 45, 46, 47, 48)

The method of any one of claims 43-48, wherein the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering of both the first and second heavy chain constant regions are F, E, and A, respectively, and wherein (i) the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the first heavy chain constant region is L, and the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the second heavy chain constant region is R, or (ii) the position corresponding to K409 in a human IgG1 heavy chain according to EU numbering of the first heavy chain is R, and the position corresponding to F405 in a human IgG1 heavy chain according to EU numbering of the second heavy chain is L.

### Claim 50 (depends on 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 43-49, wherein the constant region of said first and/or second heavy chain, such as the second heavy chain, comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of
a) the sequence set forth in SEQ ID NO: 58 or 60 [IgG1-Fc_FEAL];
b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
c) a sequence having at most 6 substitutions, such as at most 5 substitutions, at most 4 substitutions, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).

### Claim 51 (depends on 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 43-50, wherein the constant region of said first and/or second heavy chain, such as the first heavy chain, comprises or consists essentially of or consists of an amino acid sequence selected from the group consisting of
a) the sequence set forth in SEQ ID NO: 59 or 61 [IgG1-Fc_FEAR];
b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
c) a sequence having at most 6 substitutions, such as at most 5 substitutions, at most 4, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).

### Claim 52 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of any one of claims 43-51, wherein said second binding agent comprises a kappa (κ) light chain constant region.

### Claim 53 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of any one of claims 43-52, wherein said second binding agent comprises a lambda (λ) light chain constant region.

### Claim 54 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of any one of claims 43-53, wherein said first light chain constant region is a kappa (κ) light chain constant region or a lambda (λ) light chain constant region.

### Claim 55 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of any one of claims 43-54, wherein said second light chain constant region is a lambda (λ) light chain constant region or a kappa (κ) light chain constant region.

### Claim 56 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of any one of claims 43-55, wherein said first light chain constant region is a kappa (κ) light chain constant region and said second light chain constant region is a lambda (λ) light chain constant region or said first light chain constant region is a lambda (λ) light chain constant region and said second light chain constant region is a kappa (κ) light chain constant region.

### Claim 57 (depends on 52, 53, 54, 55, 56)

The method of any one of claims 52-56, wherein the kappa (κ) light chain comprises an amino acid sequence selected from the group consisting of
a) the sequence set forth in SEQ ID NO: 16,
b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
c) a sequence having at most 10 substitutions, such as at most 9 substitutions, at most 8, at most 7, at most 6, at most 5, at most 4 substitutions, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).

### Claim 58 (depends on 53, 54, 55, 56, 57)

The method of any one of claims 53-57, wherein the lambda (λ) light chain comprises an amino acid sequence selected from the group consisting of
a) the sequence set forth in SEQ ID NO: 17,
b) a subsequence of the sequence in a), such as a subsequence, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive amino acids has/have been deleted, starting from the N-terminus or C-terminus of the sequence defined in a); and
c) a sequence having at most 10 substitutions, such as at most 9 substitutions, at most 8, at most 7, at most 6, at most 5, at most 4 substitutions, at most 3, at most 2 substitutions or at most 1 substitution, compared to the amino acid sequence defined in a) or b).

### Claim 59

The method of any one of the preceding claims, wherein the second binding agent is of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

### Claim 60

The method of any one of the preceding claims, wherein the second binding agent is a full-length IgG1 antibody.

### Claim 61

The method of any one of the preceding claims, wherein the second binding agent is an antibody of the IgG1m(f) allotype.

### Claim 62

The method of an one of the preceding claims wherein the second binding agent is a bispecific antibody binding to CD40 and CD137, the bispecific antibody having i) a first heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 64 and a first light chain comprising the amino acid sequence set forth in SEQ ID NO: 65, and ii) a second heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 66 and a second light chain comprising the amino acid sequence set forth in SEQ ID NO: 67.

### Claim 63

The method of any one of the preceding claims, wherein
a) the first binding agent comprises a heavy chain variable (VH) region CDR1, CDR2, and CDR3 comprising the sequences as set forth in SEQ ID NOs: 5, 6, and 7, respectively, and a light chain variable (VL) region CDR1, CDR2, and CDR3 comprising the sequences as set forth in SEQ ID NO: 9, 10, and 11, respectively;
b) the first binding region of the second binding agent comprises a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 44, 45, and 46, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 47, YTS, and SEQ ID NO: 48, respectively; and
c) the second binding region of the second binding agent comprises a heavy chain variable region (VH) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 51, 52, and 53, respectively, and a light chain variable region (VL) comprising the CDR1, CDR2, and CDR3 sequences set forth in: SEQ ID NO: 54, GAS, and SEQ ID NO: 55, respectively.

### Claim 64

The method of any one of the preceding claims, wherein
a) the first binding agent comprises a VH region comprising the amino acid sequence set forth in SEQ ID No: 4, a VL region comprising the amino acid sequence set forth in SEQ ID No: 8;
b) the first binding region of the second binding agent comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 49 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 50; and
c) the second binding region of the second binding agent comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 56 and a light chain variable region (VL) region comprising the amino acid sequence set forth in SEQ ID NO: 57.

### Claim 65

The method of any one of the preceding claims, wherein
a) said first binding agent is an antibody comprising a VH region comprising the amino acid sequence set forth in SEQ ID No: 4, a VL region comprising the amino acid sequence set forth in SEQ ID No: 8, a CH region comprising the amino acid sequence set forth in SEQ ID No: 15, and a CL region comprising the amino acid sequence set forth in SEQ ID No: 17;
b) said second binding agent is an antibody comprising a first binding arm and a second binding arm, the first binding arm comprising the first binding region and a second binding arm comprising the second binding region;
c) the first binding arm of the second binding agent comprises a VH region comprising the amino acid sequence set forth in SEQ ID No: 49, a VL region comprising the amino acid sequence set forth in SEQ ID No: 50; a CH region comprising the amino acid sequence set forth in SEQ ID No: 60, and a CL region comprising the amino acid sequence set forth in SEQ ID No: 16; and
d) the second binding arm of the second binding agent comprises a VH region comprising the amino acid sequence set forth in SEQ ID No: 56, a VL region comprising the amino acid sequence set forth in SEQ ID No: 57, a CH region comprising the amino acid sequence set forth in SEQ ID No: 61, and a CL region comprising the amino acid sequence set forth in SEQ ID No: 16.

### Claim 66

The method of any one of the preceding claims, wherein
c) said first binding agent comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 35 and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 25;
d) said second binding agent is a bispecific antibody binding to CD40 and CD137, the bispecific antibody having i) a first heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 64 and a first light chain comprising the amino acid sequence set forth in SEQ ID NO: 65, and ii) a second heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 66 and a second light chain comprising the amino acid sequence set forth in SEQ ID NO: 67.

### Claim 67

The method of any one of the preceding claims, wherein the subject is a human subject.

### Claim 68

The method of any one of the preceding claims, wherein the tumor or cancer is a solid tumor.

### Claim 69

The method according to any one of the preceding claims, wherein said tumor is a PD-L1 positive tumor.

### Claim 70

The method of any one of the preceding claims, wherein the tumor or cancer is head and neck squamous cell carcinoma (HNSCC), such as HNSCC of the oral cavity, pharynx or larynx.

### Claim 71 (depends on 70)

The method of claim 70, wherein the HNSCC is recurrent, unresectable or metastatic.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any one of the claims 1-69, wherein the tumor or cancer is non-small cell lung cancer (NSCLC), such as a squamous or non-squamous NSCLC.

### Claim 73 (depends on 72)

The method of claim 72, wherein the NSCLC is recurrent, unresectable or metastatic.

### Claim 74 (depends on 72, 73)

The method of claim 72 or 73, wherein the NSCLC does not have an epidermal growth factor (EGFR)-sensitizing mutation and/or anaplastic lymphoma (ALK) translocation and/or ROS1 rearrangement.

### Claim 75 (depends on 72, 73, 74)

The method of any one of claims 72-74, wherein the NSCLC is NTRK1/2/3 (neurotrophic receptor tyrosine kinase 1/2/3) fusion positive, and/or has a mutation in KRAS (KRAS proto-oncogene, GTPase), BRAF (B-Raf proto-oncogene, serine/threonine kinase), or MET (MET proto-oncogene, receptor tyrosine kinase) gene, and/or has RET (ret proto-oncogene) gene rearrangements, and the subject has received prior treatment with a respective targeted therapy.

### Claim 76

The method of any one of the preceding claims, wherein the subject has received prior treatment with a PD-1 inhibitor or a PD-L1 inhibitor, such as anti-PD-1 antibody or an anti-PD-L1 antibody, preferably at least two doses of the PD-1 inhibitor or the PD-L1 inhibitor.

### Claim 77

The method of any one of the preceding claims, wherein the subject has received prior treatment with a platinum-based therapy or an alternative chemotherapy if platinum ineligible, eg a gemcitabine-containing regimen.

### Claim 78

The method of any one of the preceding claims, wherein the tumor or cancer has relapsed and/or progressed after treatment, such as systemic treatment with a checkpoint inhibitor.

### Claim 79

The method of any one of the preceding claims, wherein the subject has received at least one prior line of systemic therapy, such as systemic therapy comprising a PD-1 inhibitor or a PD-L1 inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody.

### Claim 80

The method of any one of the preceding claims, wherein the cancer or tumor has relapsed and/or is refractory, or the subject has progressed after treatment with a PD-1 inhibitor or a PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody, the PD-1 inhibitor or PD-L1 inhibitor being administered as monotherapy or as part of a combination therapy.

### Claim 81

The method of any one of the preceding claims, wherein last prior treatment was with a PD1 inhibitor or PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody, the PD-1 inhibitor or PD-L1 inhibitor being administered as monotherapy or as part of a combination therapy.

### Claim 82

The method of any one of the preceding claims, wherein the time from progression on last treatment with a PD-1 inhibitor or PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody is 6 months or less.

### Claim 83

The method of any one of the preceding claims, wherein the time from last dosing of a PD-1 inhibitor or PD-L1 inhibitor, such as an anti PD-1 antibody or an anti-PD-L1 antibody as part of last prior treatment is 6 months or less.

### Claim 84

The method of any one of the preceding claims, wherein the cancer or tumor has relapsed and/or is refractory, or the subject has progressed during or after
i) platinum doublet chemotherapy following treatment with an anti-PD-1 antibody or an anti-PD-L1 antibody, or
ii) treatment with an anti-PD-1 antibody or an anti-PD-L1 antibody following platinum doublet chemotherapy.

### Claim 85

A kit comprising
i) a first binding agent comprising at least one binding region binding to CD27 and
ii) a second binding agent comprises a first binding region binding to CD40 and a second binding region binding to CD137.

### Claim 86 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

The kit according to claim 85, wherein the first binding agent is as defined in any one of claims 1-84 and/or the second binding agent is as defined in any one of claims 1-84.

### Claim 87 (depends on 85, 86)

The kit according to claim 85 or 86, wherein the first binding agent, the second binding agent, and, if present, one or more additional therapeutic agents are for systemic administration, in particular for injection or infusion, such as intravenous injection or infusion.

### Claim 88 (depends on 85, 86, 87)

The kit according to any one of claims 85-87 for use in a method for reducing progression or preventing progression of a tumor or treating cancer in a subject.

### Claim 89 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 88)

The kit for use according to claim 88, wherein the tumor or cancer is as defined in any one of claims 1-84, and/or the subject is as defined in any one of claims 1-84, and/or the method is as defined in any one of claims 1-84.

### Claim 90

A pharmaceutical composition comprising
i) a first binding agent comprising at least one binding region binding to CD27;
ii) a second binding agent comprises a first binding region binding to CD40 and a second binding region binding to CD137; and
iii) optionally a pharmaceutical acceptable carrier.

### Claim 91 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 90)

The pharmaceutical composition according to claim 90, wherein the first binding agent is as defined in any one of claims 1-84 and/or the second binding agent is as defined in any one of claims 1-84.

### Claim 92 (depends on 90, 91)

The pharmaceutical composition according to claim 90 or 91 for use in a method for reducing progression or preventing progression of a tumor or treating cancer in a subject.

### Claim 93 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 92)

The pharmaceutical composition for use according to claim 92, wherein the tumor or cancer is as defined in any one of claims 1-84, and/or the subject is as defined in any one of claims 1-84, and/or the method is as defined in any one of claims 1-84.

### Claim 94

A first binding agent for use in a method for reducing progression or preventing progression of a tumor or treating cancer in a subject, said method comprising administering to said subject
i) the first binding agent comprising at least one binding region binding to CD27; and
ii) a second binding agent comprises a first binding region binding to CD40 and a second binding region binding to CD137.

### Claim 95 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 94)

The first binding agent for use according to claim 94, wherein the method is as defined in any one of claims 1-84, and/or the first binding agent is as defined in any one of claims 1-84, and/or the second binding agent is as defined in any one of claims 1-84.

### Claim 96

A second binding agent for use in a method for reducing progression or preventing progression of a tumor or treating cancer in a subject, said method comprising administering to said subject
i) a first binding agent comprising at least one binding region binding to CD27; and
ii) the second binding agent comprises a first binding region binding to CD40 and a second binding region binding to CD137.

### Claim 97 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 96)

The second binding agent for use according to claim 96, wherein the method is as defined in any one of claims 1-84, and/or the first binding agent is as defined in any one of claims 1-84, and/or the second binding agent is as defined in any one of claims 1-84.
